As one of the first companies in Austria, Astro Pharma has been active in the field of biosimilars since 2008 and has correspondingly extensive experience and a broad product range.
Biosimilars are high-quality follow-on biologics and make an important contribution to security of supply and optimal therapeutic options.
Astro Pharma is on the market with the biosimilar of a proven and effective TNF blocker that is administered intravenously and is particularly effective in treating Crohn’s disease and ulcerative colitis as well as rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Astro Pharma also has biosimilars of two monoclonal used in cancer therapy. These are on the one hand used with HER2 positive breast cancer, on the other hand especially/particularly for non-Hodgkin lymphoma, chronic lymphatic leukemia but also rheumatoid arthritis.
As a specialist in the biosimilar sector, Astro Pharma aims to expand its product range and to be an important partner of the Austrian healthcare system.
|Product name||Active component|
|Herzuma® 150 mg powder for concentrate for solution for infusion||Trastuzumab|
|Herzuma® 420 mg powder for concentrate for solution for infusion||Trastuzumab|
|Remsima® 100 mg powder for concentrate for solution for infusion||Infliximab|
|Truxima® 100 mg concentrate for solution for infusion||Rituximab
|Truxima® 500 mg concentrate for solution for infusion||Rituximab
|Yuflyma® 40 mg solution for injection in pre-filled pen||Adalimumab
|Yuflyma® 40 mg solution for injection in pre-filled syringe||Adalimumab